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Abstract
Tuberculosis (TB) continues to pose a serious challenge to human health afflicting a large number of people throughout the
world. In spite of the availability of drugs for the treatment of TB, the non-compliance to 6–9 months long
chemotherapeutic regimens often results in the emergence of multidrug resistant strains of Mycobacterium tuberculosis
adding to the precariousness of the situation. This has necessitated the development of more effective drugs. Thiamin
biosynthesis, an important metabolic pathway of M.tuberculosis, is shown to be essential for the intracellular growth of this
pathogen and hence, it is believed that inhibition of this pathway would severely affect the growth of M.tuberculosis. In this
study, a comparative homology model of M.tuberculosis thiamin phosphate synthase (MtTPS) was generated and employed
for virtual screening of NCI diversity set II to select potential inhibitors. The best 39 compounds based on the docking results
were evaluated for their potential to inhibit the MtTPS activity. Seven compounds inhibited MtTPS activity with IC50 values
ranging from 20 – 100 mg/ml and two of these exhibited weak inhibition of M.tuberculosis growth with MIC99 values being
125 mg/ml and 162.5 mg/ml while one compound was identified as a very potent inhibitor of M.tuberculosis growth with an
MIC99 value of 6 mg/ml. This study establishes MtTPS as a novel drug target against M.tuberculosis leading to the
identification of new lead molecules for the development of antitubercular drugs. Further optimization of these lead
compounds could result in more potent therapeutic molecules against Tuberculosis.
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Introduction
Thiamin pyrophosphate (TPP), an important cofactor for several
enzymes such as pyruvate dehydrogenase, transketolase, 2-oxogluta-
rate dehydrogenase and acetohydroxyacid synthase, is involved in
cleaving the carbon-carbon bonds adjacent to a carbonyl group thus
playing an important role in various processes such as glycolysis, TCA
cycle, pentose phosphate pathway and metabolism of branched chain
amino acids [1–5]. Hence, maintaining the adequate levels of TPP
and TPP-utilizing enzymes is essential to all known cellular life forms.
However, while most microorganisms can synthesize thiamin de novo,
animals and many fungi require thiamin or its immediate precursors
as a supplement in their diet. Thiamin phosphate synthase (TPS) is a
bacterial protein involved in the biosynthesis of thiamin pyrophos-
phate (TPP), the active form of thiamin (vitamin B1) [6]. Thiamin
phosphate synthase (ThiE) of Mycobacterium tuberculosis, the product of
the last gene of thiamin biosynthetic pathway (rv0414c), has been
identified as an in vivo essential enzyme for the pathogen,
emphasizing its importance as a potential drug target [7]. Unlike
most microorganisms, M.tuberculosis does not contain the genes for
thiamin salvage pathway and transporters [8] further substantiating
the importance of thiamin biosynthesis for the pathogen’s survival
thus making TPS an attractive target for the development of
antitubercular drugs. It catalyzes the substitution of pyrophosphate
of 2-methyl-4-amino-5-hydroxymethylpyrimidine pyrophosphate
(HMP-PP) by 4-methyl-5-(beta-hydroxyethyl) thiazole phosphate
(Thz-P) to yield thiamin phosphate in the thiamin biosynthesis
pathway, which is further phosphorylated to thiamin pyrophos-
phate (TPP) [6,9,10]. Although, TPS represents a very important
enzyme for the survival of microorganisms, till date it has not been
exploited as a drug target and no inhibitor against it has been
identified. In this work, we generated a three dimensional homology
model for M.tuberculosis thiamin phosphate synthase (MtTPS) and
carried out virtual screening with National Cancer Institute (NCI)
diversity set II containing 1541 compounds with nonredundant
pharmacophore profiles against the substrate cavity of the enzyme.
Further the shortlisted compounds were evaluated for the inhibition
of thiamin phosphate synthase activity in vitro as well as the growth
of M.tuberculosis in broth culture. This study for the first time
emphasizes the importance of MtTPS as a target for the
development of new interventions against M.tuberculosis.
Results
Cloning, Expression and Purification of MtTPS
thiE (rv0414c) was cloned in pET28a and expression was carried
out as described in materials and methods. The localization of the
expressed protein was analyzed by SDS electrophoresis using a
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observed at an apparent molecular weight of ,29 kDa with the
entire recombinant protein localizing in the insoluble fraction,
when the induction was carried out at 37uC (data not shown). In
order to enhance the solubility of MtTPS, its expression was also
evaluated at 25uC and 15uC. The induction at 25uC also resulted
in the localization of majority of the protein in the insoluble
fraction (data not shown), however, at 15uC, 10% of the expressed
MtTPS localized in the soluble fraction (Figure S1a, lane 7), which
was purified by strep - tactin affinity chromatography as described
in materials and methods and the purified enzyme was found to be
,80% pure (Figure S1b, lanes 5–10).
Determination of the enzymatic activity of MtTPS
E.coli ThiD or HMP-kinase was purified to ,95% purity (Figure
S2) and was used for the enzymatic synthesis of HMP-PP that is
required as one of the substrates for TPS. The activity of MtTPS
was measured by the thiochrome assay as described in materials
and methods. The specific activity of MtTPS was determined to be
1.82 nmoles/min/mg as opposed to 65 nmoles/min/mg reported
for E.coli TPS (EcTPS) [11,12]. The Michaelis Menten constants
or the Km values of the substrates HMP-PP and Thiazole-P were
determined to be 5 mM and 14 mM, respectively (Figure S3).
Homology modeling of MtTPS
The preliminary similarity search for MtTPS amino acid
sequence by using NCBI BLAST server [13] against the PDB
database exhibited the highest homology with thiamin phosphate
synthase from Pyrococcus furiosus (PfTPS, 1XI3 – unpublished data)
and Bacillus subtilis (BsTPS, 2TPS) [14,15] (data not shown).
Multiple sequence alignment by using ClustalW [16] displayed
34.3% identity and 67.6% similarity between MtTPS and PfTPS,
while MtTPS and BsTPS shared 28.8% identity and 66.6%
similarity (Figure S4). Based on the BLAST results, the top four
hits (PfTPS: PDB ID - 1XI3 and BsTPS: PDB ID - 2TPS, 1G4P
and 1G4E) were analyzed. The structures with PDB ID - 2TPS
and 1G4P were not considered further for model building since
2TPS represented the crystal structure of BsTPS complexed with
the reaction products thiamin phosphate and pyrophosphate [14],
while 1G4P represented the crystal structure of an S130A mutant
of BsTPS complexed with 4-amino-2-trifluoromethyl-5-hydroxy-
methylpyrimidine pyrophosphate (CF3HMP-PP) [15]. 1XI3 and
1G4E represented structures without any ligand and therefore
were considered suitable for generating the homology model for
MtTPS. Based on the crystal structures of PfTPS and BsTPS,
three-dimensional homology models for MtTPS were generated
by two online protein modeling servers: SWISS-MODEL [17,18]
and ESyPred3D [19]. Table 1 shows the total energy calculated
for the top models generated by these softwares as analyzed by
using DeepView-Swiss pdb Viewer [20]. The MtTPS model
generated by using SWISS-MODEL server [17,18] with PfTPS
structure as the template was selected for further work due to the
highest overall negative energy of this structure (TPS_1X13).
Besides, MtTPS exhibited higher sequence similarity with PfTPS
as compared to BsTPS. Further, the stereochemical quality of the
model was assessed by PROCHECK [21]. The results showed
that the backbone W and Y dihedral angles of 87.5%, 8.7%, 2.2%
of the residues were located in the most favoured, additionally
allowed and generously allowed regions of the Ramachandran
plot, respectively, with only 3 residues (1.6%) in the disallowed
regions (Table 2, Figure S5). It was verified that none of the
residues belonging to the disallowed region were located in the
active site, thus validating the overall stereochemical quality of the
MtTPS model. Further, the model was evaluated by using
PROSA [22,23], PRO-Q [24], VERIFY3D [25,26], and ERRAT
[27]. The results obtained from these programs imply that the
residues in the model are placed in very good overall configuration
(Table 2 and Figure S6, S7). The MtTPS model was subjected to
energy minimization by using the AMBER9 software [28] by
applying the forcefield ‘ff03’ and 500 cycles of minimization.
Salient features of MtTPS structure
Thiamin phosphate synthase belongs to the family of a/b
proteins with a triosephosphate isomerase fold (TIM barrel) having
an inner core of 8-a helices and eight parallel b-strands tilted
approximately 45u from the axis of the barrel (Figure 1a). The
BsTPS active site is primarily formed by the three loops spanning
the central cavity of the structure and is covered by the largest loop
[14,15]. The substrate binding groove of the TPS lies in the area
surrounded by the b-barrel structure present in the central area of
the TIM-fold structure of TPS. The residues from the b-strands
pointing towards the interior of the barrel form a hydrophobic
core and provide interactions for binding to the substrate [14,15].
Upon visual comparison of the active site groove, it was found that
it is narrower and less deep in the structure of MtTPS as compared
to the crystal structures of PfTPS and BsTPS (Figure 1b and 1c,
substrate binding groove of BsTPS not shown).
Virtual screening for the identification of inhibitors
against MtTPS
NCI diversity set II containing 1541 diverse compounds was
virtually screened against the MtTPS model with the substrate
binding groove or the HMP-PP binding site as the target for
docking by using Autodock4 [29] and DOCK6 [30] (Figure 2a).
This library set was selected owing to the tremendously diverse
nature and pharmacologically desirable features of the compounds
in this collection. To assess the accuracy of the docking procedures
and the parameters employed in the docking, CF3HMP-PP (an
analog of HMP-PP, the natural substrate of TPS) was docked to
the MtTPS structure and was compared with the X-ray structure
of BsTPS bound to this ligand (Figure 2b). The result verified the
accuracy of the docking procedures and the parameters employed
as seen by the correct docking as well as the orientation of the
ligand docked by both the softwares (Figure 2c and 2d). Scoring
system used by Autodock4 [29] and DOCK6 [30] are based on
different algorithms and a direct comparison of these results is not
Table 1. Energy calculations for top models of MtTPS generated by SWISS-MODEL and ESyPred3D.
Homology model by using 1XI3 as template
(TPS_1XI3)
Homology model by using 1G4E as template
(TPS_1G4E)
SWISS-MODEL structure 25577.096 24400.27
ESyPred3D structure 596.321 850.032
doi:10.1371/journal.pone.0022441.t001
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direct comparison of the results generated by the two docking
softwares, X-Score [31] was used. X-Score [31] takes the output
files of the docking softwares as input file for recalculation of the
docked conformation of the molecules and re-ranks the molecules
according to its own algorithm. The best 40 compounds based on
the docking results and re-ranking were requested from National
Cancer Institute - Developmental Therapeutics Program (NCI-
DTP), out of which 39 compounds were obtained and exper-
imentally screened in order to assess their ability to inhibit the
MtTPS activity. Table S1 shows the list and ranking of the
compounds obtained from NCI-DTP, while the chemical
structures of the compounds are given in supporting information
S1. It may be stated that NCI diversity set II is comprised of the
molecules having pharmacologically desirable features. It was
further verified by the fact that during X-Score analysis, when the
ligand pre-screening option was enabled (to assess drug-like
properties), none of the molecules in this set was excluded from
the scoring (data not shown).
Evaluation of inhibitory potential of the compounds
against MtTPS activity
The potential of the compounds to inhibit MtTPS activity was
measured at a concentration of 100 mg/ml in the normal assay
conditions as described in the materials and methods section.
Among the 39 compounds evaluated, 25 exhibited inhibition of
the MtTPS activity with seven compounds (9, 10, 11, 12, 23, 33
and 35) exhibiting greater than 20% inhibition and were therefore
selected for further studies (Figure 3). IC50 values of the selected
seven compounds were determined at the HMP-PP concentration
of 5 mM (the Km value) by measuring the inhibition of MtTPS
activity in the presence of varying concentrations of these
compounds (Table 3). It was observed that compounds 23 and 9
exhibited the highest inhibition of MtTPS activity with IC50 values
Table 2. Evaluation of MtTPS homology model by using PROCHECK, PROSA, PRO-Q, VERIFY3D and ERRAT online protein structure
evaluation tools.
PROCHECK (R.C.Plot analysis) TPS_1XI3
1. Favoured 87.5%
2. Additionally allowed 8.7%
3. Generously allowed 2.2%
4. Disallowed 1.6% (3 residues)
PROSA
1. Z Score 27.08
2. Local model quality No positive regions
PRO-Q
1. LG score 4.551
(.1.5 fairly good, .2.5 very good, .4.0 extremely good) (extremely good)
2. MAX-SUB score 0.460
(.0.1 fairly good, .0.5 very good, .0.8 extremely good) (close to very good)
VERIFY 3D
Number of residues with score .0.2 90.45% (pass)
ERRAT
Overall quality factor 61.611%
doi:10.1371/journal.pone.0022441.t002
Figure 1. Comparative homology modeling based three-dimensional structure of MtTPS. (a) The overall structure of MtTPS showing the
characteristic triosephosphate isomerase fold. The binding site groove of MtTPS (b) and PfTPS (c) is shown and the depth of the binding site groove is
encircled. The structure is shown from a side view rotated 90 degrees along the vertical axis with respect to the top view. The figures were prepared
by using Pymol Molecular viewer [56].
doi:10.1371/journal.pone.0022441.g001
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compound 10 was determined to be 70 mg/ml. Compounds 12
and 33 displayed 50% inhibition of the activity at a concentration
of 100 mg/ml, while the IC50 values of compounds 11 and 35 were
estimated to be .100 mg/ml.
Determination of MIC99 values of selected compounds
against M.smegmatis and M.tuberculosis
To quickly obtain the preliminary information about their
inhibitory potential, the seven active compounds were first
examined for their inhibitory activity against M.smegmatis, a fast
growing species of mycobacteria by using broth macrodilution
method and the results are summarized in table 3. Compounds 10
and 35 exhibited no inhibition of M.smegmatis growth even upto a
concentration of 750 mg/ml. Compounds 9 and 12 exhibited 32%
and 45% inhibition of M.smegmatis growth, respectively, at a
concentration of 750 mg/ml. Compounds 11 and 33 showed the
highest inhibition of M.smegmatis growth with MIC99 values being
125 mg/ml and 150 mg/ml, respectively. Compound 23 exhibited
a moderate inhibition of M.smegmatis growth with an MIC99 value
of 500 mg/ml (Table 3, Figure 4).
After the preliminary studies with M.smegmatis, these compounds
were evaluated for their potential to inhibit the growth of
M.tuberculosis, the pathogen that causes tuberculosis. The results
revealedthatcompound12showedonlymarginalgrowthinhibition
of ,32% even upto a concentration of 750 mg/ml. Compounds 11,
23 and 10 displayed MIC99 values of 250 mg/ml, 300 mg/ml and
750 mg/ml, respectively with compounds 35 and 33 exhibiting a
significant inhibition with MIC99 values of 125 mg/ml and
Figure 2. Verification of the docking procedures of Autodock4 and DOCK6. (a) A Ribbon representation of MtTPS structure is shown in a
side view rotated 90 degrees along the vertical axis with respect to the top view. The grid used for the docking of ligands is shown in a box
representation. (b) The ligand CF3HMP-PP bound at the active site of BsTPS in the X-ray crystal structure (PDB ID- 1G4P). Ligand docked by Autodock4
(c) and DOCK6 (d) at the active site of MtTPS. The ligand is shown in orange stick model. Figure (a) was prepared by software Autodock4 while the
rest of the figures were prepared by using Pymol Molecular viewer [56].
doi:10.1371/journal.pone.0022441.g002
Figure 3. Evaluation of the compounds for their potential to
inhibit the activity of MtTPS. Bar diagram represents percent
inhibition of MtTPS activity in the presence of compounds at a
concentration of 100 mg/ml. The data depicts the values as mean 6 S.E.
of two separate experiments carried out in duplicates.
doi:10.1371/journal.pone.0022441.g003
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significant inhibition with an MIC99 value of 6 mg/ml (Table 3,
Figure 4). These results were verified several times to rule out any
possibility of the presence of impurity or contamination in the
culture, which might be inhibitory to mycobacterial growth. In
addition, to rule out the action of compound 9 due to any toxic
effect on the cells, we examined the cytotoxicity of compound 9 on
variouscell lines includingTHP-1, HeLa, HepG2 and HuH cells by
trypan blue exclusion method. We observed that compound 9
showed no significant cytotoxic effect on any of these cells up to a
concentration of 25 mg/ml (Figure 5).
Discussion
Thiamin biosynthetic pathway represents an attractive target for
the development of antitubercular drugs due to its essential
requirement for the survival of M. tuberculosis. The thiE specifically
figures amongst the index of genes reported to be essential for the
in vivo growth of M.tuberculosis [7]. Besides, in a path breaking study
by employing transposon site hybridization (TraSH), Sassetti et al.
have also identified thiamin biosynthetic genes to be essential for
M.tuberculosis in vitro [32]. Thiamin is indispensable for the activity
of carbohydrates and branched chain amino acid metabolizing
enzymes [5], therefore, it is an essential cofactor for all organisms.
Its absence severely limits the availability of carbon source
required for the growth of the organism. It has been illustrated
clearly that thiamin auxotrophy, for example, in the case of
Arabidopsis, leads to loss of viability [33,34]. However, this is not a
stand-alone example as it has also been shown in many other cases
of auxotrophy. For example, inositol auxotrophs of Neurospora [35]
and inositol – requiring species of yeast die logarithmically when
starved for inositol [36,37,38]. Saturated fatty acid auxotrophs
behave similarly during fatty acid starvation [39] and biotin or
pantothenate requiring organisms when starved for their require-
ments do not survive either [40,41,42]. More close to the context
of this study, NAD
+ auxotrophy is shown to be bacteriocidal for
M.tuberculosis [43]. Indeed, the salvage and transport pathways
present in most bacteria can sometimes complement de novo
biosynthesis and cripple the value of such an auxotrophic situation.
However, M. tuberculosis represents a unique case in that it lacks
both the salvage pathways as well as transporters of thiamin [8],
which has provided unique importance to thiamin biosynthesis as
a target for developing new drugs against this pathogen. The
absence of thiamin biosynthesis genes in humans makes it even
more exclusive target for the development of new TB drugs.
Thiamin phosphate synthase or ThiE catalyzes the final step in the
synthesis of thiamin phosphate. Recently, a number of inhibitors
against various targets have been successfully identified by
employing structure based drug designing using virtual screening
[44,45,46]. Hence, the importance of this approach in discovering
new lead molecules and drugs against various diseases cannot be
overemphasized.
In this study, a three – dimensional homology model of
M.tuberculosis thiamin phosphate synthase was constructed by using
the X-ray crystal structure of thiamin phosphate synthase from
Pyrococcus furiosus, since the crystal structure of MtTPS was not
available. Examination of the substrate binding groove of MtTPS,
PfTPS and BsTPS revealed that the substrate binding groove of
MtTPS is narrower and shallower as compared to its counterparts
in PfTPS and BsTPS. A comparison of the residues in the binding
site groove showed that although most residues in this region were
identical in case of all the three enzymes, three of the residues were
distinctly different in case of MtTPS. Gly
125, Val
158 and Gly
178,
the short chain residues present in PfTPS and the corresponding
residues Gly
136, Val
171 and Gly
191 in BsTPS are replaced by long
chain residues namely Cys
139, Phe
174 and Arg
194 in the case of
MtTPS, which may possibly be responsible for the narrower
binding groove of the latter (Figure 6a). This lack of depth of
binding site groove in case of MtTPS may be responsible for its
reduced affinity for substrate binding. Infact, when residues
Cys
139, Phe
174 and Arg
194 of MtTPS were in silico mutated to Gly,
Val and Gly, respectively, it resulted in much deeper and broader
substrate binding groove (Figure 6b and 6c). E.coli TPS (EcTPS)
also has short chain residues in these positions at the active site as
represented by Ala
127, Val
162 and Ser
182. Although, the activity of
PfTPS and BsTPS is not reported in the literature, EcTPS has 30-
40 times higher activity than MtTPS substantiating the notion that
the presence of long chain residues in case of MtTPS leads to
reduction in its enzymatic activity. However, it must be mentioned
that a relatively lower activity exhibited by MtTPS in comparison
to its E.coli counterpart is well suited for the slow growing nature of
M.tuberculosis.
Computational screening approach was employed to identify
potential small-molecule inhibitors of MtTPS from the NCI
diversity set II comprising of 1541 compounds. Out of the 39
selected compounds evaluated for their inhibitory activity,
compound 9 (4-{[(2-hydroxy-5-nitrophenyl)methylidene]amino}-
5-methyl-2-(propan-2-yl)phenol), 33 (3-benzylsulfanyl-phenan-
thro[9,10-e][1,2,4]triazine) and 35 (Coumarin, 7-[[4-chloro-6-
(diethylamino)-s-triazin-2-yl]amino]-3-phenyl-) were identified as
potential inhibitors of M.tuberculosis growth. All these compounds
exhibited inhibition of MtTPS enzymatic activity as well as the
growth of M. tuberculosis in broth culture. However, compound 9
exhibited the highest efficacy with an MIC99 value of 6 mg/ml. In
addition, it did not exhibit any significant toxicity in various cell
lines till a concentration of 25 mg/ml and also adhered to the
Table 3. IC50 and MIC99 values of the top seven compounds.
S. No. Compd. NSC number IC50 (m/ml) MIC99 for M.smegmatis (mg/ml) MIC99 for M.tuberculosis (mg/ml)
1 9 33472 34 32% inhibition at 750 mg/ml 6
2 10 37168 70 No inhibition 750
3 11 42199 .100 125 250
4 12 50648 100 45% inhibition at 750 mg/ml 32% inhibition at 750 mg/ml
5 23 116720 20 500 300
6 33 327702 100 150 162.5
7 35 338963 .100 No inhibition 125
doi:10.1371/journal.pone.0022441.t003
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provided key insights into the likely binding sites (Figure 7a). The
compound 9 or NSC 33472 is docked at the large hydrophobic
pocket at the active site of MtTPS. The aromatic ring A is placed
in a hydrophobic environment surrounded by Ile
173, Val
193 and
Phe
171 while the two oxygen atoms of the nitro group appear to be
making hydrogen bonds with the hydrogen atoms of the adjacent
Cys
136 and Cys
11 both present within 2.5A ˚ distance from the
oxygen atoms. Moreover, the hydroxyl group of the aromatic ring
B can form hydrogen bond with the carboxyl group of Asp
98
Figure 4. Effect of compounds on the viability of M.smegmatis and M.tuberculosis. The data depicts the values as mean 6 S.E. of two
separate experiments.
doi:10.1371/journal.pone.0022441.g004
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9 in the presence of varying concentrations of the substrate HMP-
PP (Figure 7b) showed that an enhancement in the concentration
of the substrate causes a decline in the inhibition and vice versa,
which clearly indicates that compound 9 inhibits MtTPS by
competing with HMP-PP for binding at the active site thus
substantiating the docking results.
In conclusion, we have identified a promising lead molecule
(compound 9) for the development of sterilizing agents against
M.tuberculosis and further efforts are being made to optimize and
enhance the inhibitory potency of this lead compound. The other
two weakly active compounds (compound 33 and 35) would also
be exploited further to design more potent molecules. Efforts will
also be diverted towards the identification of new compounds
having a better inhibitory potential. In addition, we anticipate that
selective inhibition of thiamin biosynthetic enzymes would prove
to be a promising strategy for the identification of effective
compounds against mycobacterial infections.
Materials and Methods
Materials, bacterial strains and growth conditions
Molecular biology methods employed in this study were
performed according to the standard protocols by Sambrook
and Russell [47]. Plasmid pET16b/thiD and HMP were kind gifts
from Prof. T. P. Begley (Department of Chemistry, Texas A&M
University). Thiazole-phosphate was synthesized by Jubilant
Chemsys Ltd., Noida, India by using the protocol described by
Williams et al [48] and Camiener et al [49]. The compounds were
obtained from the Drug Synthesis and Chemistry Branch,
Developmental Therapeutics Program, Division of Cancer
Treatment and Diagnosis, National Cancer Institute, National
Institutes of Health. Potassium ferricyanide (K3FeCN6) and H2O2
were procured from Thermo Fisher Scientific India Ltd. (Sion,
Mumbai, India). Isobutanol was procured from Qualigens fine
chemicals (Dr. Annie Besant Road, Mumbai, India) and all other
reagents were obtained from Sigma-Aldrich Inc. (St. Louis, MO,
USA). Ni-NTA and strep - tactin superflow resin were procured
from IBA (Goettingen, Germany). RPMI medium and FCS (fetal
calf serum) were obtained from Invitrogen Corporation (Carlsbad,
California, USA). E.coli BL21 (lDE3) cells were grown in Luria
Bertani (LB) broth at 37uC with constant shaking at 200 rpm.
Figure 5. Evaluation of compound 9 for its cytotoxic effect on
various cell lines. Cell viability of THP-1, HeLa, HepG2 and HuH cells
in the presence of varying concentrations of compound 9.
doi:10.1371/journal.pone.0022441.g005
Figure 6. Differences in the binding site of MtTPS. (a)
Comparison of the residues at the binding site groove. The structures
of MtTPS and PfTPS are superimposed (wheat colour), CF3HMP-PP is
bound at the binding site (yellow colour), residues Cys
139, Phe
174 and
Arg
194 of MtTPS (red) and corresponding Gly
125 ,Val
158, Gly
178 of PfTPS
(blue) are shown in stick model. (b) Molecular surface representation of
the mutated MtTPS structure. In-silico substitutions of Cys
139, Phe
174
and Arg
194 in the MtTPS structure by Gly, Val and Gly resulted in a much
deeper active-site groove than in the original structure. (c) Molecular
surface representation of the original MtTPS structure. The depth of the
groove is encircled. The figures were prepared by using Pymol
Molecular viewer [56].
doi:10.1371/journal.pone.0022441.g006
Thiamin Phosphate Synthase Inhibitors
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2155 and M.tuberculosis H37Rv were grown by using
either Difco Middlebrook (MB) 7H9 supplemented with 0.5%
glycerol, 0.2% tween280 at 37uC with constant shaking at
200 rpm or on Difco Middlebrook 7H11 agar. In case of
M.tuberculosis, the medium was supplemented by Albumin-
Dextrose-Catalase (ADC). The Difco Middlebrook media and
ADC were obtained from Becton Dickinson and Company
(Sparks, MD, USA). Whenever appropriate, antibiotics were
added at a concentration of 50 mg/ml ampicillin (Amp) and
25 mg/ml Kanamycin (Kan).
Cloning and expression of thiE gene
thiE gene of M.tuberculosis (rv0414c) was previously cloned in
pBEn-SET3a vector at BamHI and HindIII sites (unpublished
data). The sequence of the gene was derived from EMBL/
Genbank. 59gaattcggatccgctagcgtgcacgaatcccgtctggc39 containing
BamHI and NheI site was used as the forward primer and
59gaattcaagcttattatttcgaactgcgggt-ggcccaaagcgctgttcgctgctgtaagcg-
ccgac39 containing strep tag-stop-HindIII site was used as reverse
primer for PCR amplification. thiE gene was excised from
recombinant plasmid pBEn-3a/thiE by restriction digestion with
NheI/HindIII restriction enzymes. The resulting thiE gene was
cloned into pET28a digested with NheI and HindIII and the
resulting plasmid pET28a/thiE was used for expression studies.
For expression of thiE, E.coli BL21 (lDE3) cells transformed with
pET28a/thiE were grown to mid-logarithmic phase in LB media
containing 25 mg/ml of kanamycin and synthesis of MtTPS
protein was induced by the addition of 1 mM isoproryl-1-thio-b-
D-galactopyranoside (IPTG) followed by harvesting of the cells
after incubation at 37uC (3 hours), 25uC (6 hours) or 15uC( 1 6
hours) with a constant shaking at 200 rpm.
Purification of MtTPS
After induction at 15uC, the E.coli cells from a 2 litre LB culture
were harvested by centrifugation at 4uC, 6000 g for 10 minutes
and resuspended in 25 ml of resuspension buffer (20 mM Tris-
HCl, 50 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF),
2m Mb-mercaptoethanol, pH 8.0) followed by sonication. After
sonication, the cell lysate was centrifuged at 12,000 g for 1 hour at
4uC and the supernatant was loaded onto a pre-equilibrated 4 ml
strep - tactin superflow column. The column was then washed with
4 column volumes of wash buffer (20 mM Tris-HCl, 50 mM
NaCl, pH 8.0) and protein was eluted in 1 ml fractions by using
elution buffer (wash buffer +2.5 mM desthiobiotin). After
determining the protein concentration by Bradford assay [50],
the fractions were analyzed by SDS-PAGE using a 12.5% gel and
the fractions containing TPS were pooled and concentrated by
using Amicon Ultra protein concentrator (Millipore, Billerica,
MA, USA) with a 5 kDa cutoff filter. NaCl and desthiobiotin were
removed from the purified sample by passing it through a G-25
column (7 ml) equilibrated with 20 mM Tris-HCl, pH 8.0 and the
purified protein was stored at 220uC in aliquots after adding 10%
glycerol and 1 mM DTT.
Purification of E.coli ThiD and preparation of HMP-PP
BL21 (lDE3) cells were transformed with plasmid pET16b/
thiD (carrying the gene for E.coli HMP-kinase or thiD) and the
transformants were used to inoculate 2 liter LB media with 50 mg/
ml ampicillin followed by growth to an A600nm of 0.8–1.0 at 37uC.
After 16 hours of induction with 1 mM IPTG at 15uC, the cells
were harvested and resuspended in approximately 25 ml of
resuspension buffer (20 mM Tris-HCl, 50 mM NaCl, 10 mM
imidazole, 1 mM PMSF, 2 mM b-mercaptoethanol, pH 8.0)
followed by sonication. After sonication followed by centrifugation
for 1 hour at 12,000 g at 4uC, the supernatant was subjected to
purification by Ni-NTA affinity chromatography. Briefly, the
clarified lysate was mixed with 3 ml Ni-NTA resin, on a rocker for
1 hour at 4uC, unbound proteins removed by centrifugation at
2000 g for 2 minutes and the resin was washed twice with the
resuspension buffer. For higher stringency, washings were
repeated twice with resuspension buffer containing 20 mM
imidazole followed by one more round of washing with
resuspension buffer containing 50 mM imidazole. The protein
was eluted by using resuspension buffer containing 250 mM
imidazole in 1.5 ml fractions followed by protein estimation and
dialysis of the pooled fractions against 20 mM Tris-HCl, pH 8.0.
The purified protein was stored at 280uC after the addition of
10% glycerol and 1 mM DTT.
The HMP-PP was prepared as described earlier [51]. Briefly, a
0.08 mM stock solution of HMP-PP was prepared by adding
640 mg of HMP-kinase (ThiD) to a 500 ml solution containing
0.1 mM HMP and 2.5 mM ATP in reaction buffer (6 mM MgCl2
+100 mM Triethanolamine-HCl, pH 8.0) followed by incubation
at 25uC for 30 minutes. ThiD converts HMP to HMP-PP with
concomitant production of ADP. The latter can be monitored by
its subsequent utilization in an NADH dependent Pyruvate Kinase
(PK) and Lactate Dehydrogenase (LDH) coupled reaction [52].
For every 2 molecules of ADP formed, 1 molecule of HMP-PP is
Figure 7. Interaction of compound 9 with the active site of MtTPS and its mode of action. (a) Binding mode of compound 9 (NSC33472) at
the active site of MtTPS. The figure was prepared by using Pymol Molecular viewer [56]. (b) Inhibition of MtTPS activity by compound 9 in the
presence of varying concentrations of HMP-PP.
doi:10.1371/journal.pone.0022441.g007
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reaction without further purification as ADP, ATP and HMP-
Kinase are known not to interfere in the assay.
Thiamin phosphate synthase assay
The activity of thiamin phosphate synthase was measured by
using the thiochrome assay as described earlier [51,53]. Briefly,
the reaction mixture (500 ml) contained 50 mM Tris-HCl
(pH 7.5), 6 mM MgSO4,2 5 mg MtTPS, 100 mM Thz-P and
100 mM HMP-PP. Reaction was carried out at 37uC for 2 hours.
Following this, aliquots of 60 ml were removed, reaction was
terminated with 60 ml of 10% TCA followed by centrifugation at
12000 g for 2 minutes to remove the proteins and to 100 mlo f
each resulting clarified solution, 200 ml of 4 M potassium acetate
was added. Potato acid phosphatase (type –II) was then added
(100 ml of 2 mg/ml solution) and the mixture was incubated for
1h r a t 3 7 uC. The resulting thiamin (THI) was oxidized to
thiochrome by the addition of 100 ml of 3.8 mM K3FeCN6 in 7 M
NaOH, immediately followed by thorough mixing. The reaction
was quenched after 30 seconds by the addition of 100 ml of 0.06%
H2O2 in 5.5 M KH2PO4, diluted with 400 ml of water, and then
extracted with 800 ml of isobutanol and centrifuged at 12000 rpm
for 10 minutes. After phase separation, 800 ml of the organic phase
was transferred to a flourescence cuvette and the thiochrome
fluorescence was recorded on fluorimeter (Cary Eclipse Floures-
cence spectrophotometer, Varian Inc., Santa Clara, CA, USA)
with an excitation wavelength of 389 nm and emission wavelength
of 434 nm.
Homology modeling of MtTPS
Amino acid sequence similarity search was performed by using
the NCI BLAST server [13] with PDB structure database as the
search set. Based on the BLAST results, the first few potential hits
were aligned with the MtTPS sequence by using the program
ClustalW [16]. The resulting alignments were then submitted for
automatic model building of MtTPS by using SWISS-MODEL
server [17,18]. Comparative homology modeling was also
attempted by using online software ESyPred3D [19].
Virtual screening
The NCI diversity set II containing 1541 compounds was
selected for virtual screening and docking was performed by using
Autodock4 [29] and DOCK6 [30] and re-ranking of the docked
ligands was carried out by software X-Score [31]. The three-
dimensional co-ordinates for the ligands already processed in the
pdbqt format required for autodock were obtained from the
autodock database website [54]. The substrate binding cavity or
the HMP-PP binding site was targeted for docking. The docking
parameters for Autodock4 included the genetic algorithm,
1750000 energy evaluations and 20 runs. Each docking took an
average of 10 minutes per processor per ligand. 194 ligands
resulted in higher binding energies than the positive control
(CF3HMP-PP) and the pdbqt files of these docked ligands were
extracted from the log files (dlg), which were subsequently
converted to pdb format. All the ligands in the pdb format were
then written to a single multi-mol2 file using the software chimera
[55], which was used for re-ranking by X-Score [31].
The ligands in the pdbqt format obtained from autodock
database website [54] were processed in order to use them with
software DOCK6 [30]. The 1541 pdbqt files were converted to
pdb format and then into a single multi-mol2 file by using the
software chimera [55], to which charges and hydrogen atoms
were added with Accelrys Discovery Studio 2.5 (Accelrys
Software Inc., San Diego 92121, CA, USA) and the final mol2
file was used for virtual screening with DOCK6 [30]. Re-ranking
of the results obtained from both the docking softwares was
carried out by using the X-Score [31] software using default
parameters with the ligand pre-screening option enabled to
screen the molecules based on the Lipinsky rules (molecular
weight, logP, and number of H-bond donor and acceptor atoms).
Only the molecules that complied with the rules or had the drug-
like properties were considered in the scoring. Top 40
compounds were requested from NCI/DTP based on the
comparison of Autodock4 results, DOCK6 results and X-Score
applied to Autodock4 and DOCK6 results and 39 compounds
were finally obtained for biochemical screening.
Inhibitory activity of compounds and determination of
IC50 values
All the compounds were dissolved in DMSO at a concentration
of 1.6 mg/ml. 25 mg of purified MtTPS and 30 ml of respective
compounds (final conc. – 100 mg/ml) in a total volume of 105 ml
by using reaction buffer were incubated at 37uC for 10 minutes
before proceeding with the MtTPS assay as described above. In
the control samples, the compounds were replaced with the same
volume of DMSO. Compounds displaying .20% inhibition of the
enzyme activity were screened at multiple concentrations (5–
300 mg/ml) and the activity was measured by using 5 mMo f
HMP-PP. IC50 values (concentration of the compound resulting in
50% inhibition of the enzymatic activity) were determined from
the dose-response curves.
Determination of Minimum Inhibitory Concentration
M.smegmatis mc
2155 or M.tuberculosis H37Rv was grown in MB
7H9 - tween media (ADC was added to the media in case of
M.tuberculosis) till early-logarithmic phase (A600nm of 0.8) and the
cells were subsequently diluted to an A600nm of 0.02 (,2610
6 cfu/
ml) in respective media. 1 ml aliquots of this culture were
incubated with varying concentrations of the compounds along
with the controls (containing appropriate concentrations of
DMSO) for 24 hours (M.smegmatis) or 7 days (M.tuberculosis)a t
37uC with constant shaking at 200 rpm. The cultures were serially
diluted with MB 7H9 media and CFU was determined by plating
on MB 7H11 agar plates after incubation at 37uC for 3–4 days
(M.smegmatis) or 3–4 weeks (M.tuberculosis). MIC99 value is the
concentration of the compound which resulted in 99% inhibition
of the growth.
Cytotoxicity assay
The cytotoxicity of compound 9 was assessed by employing
THP-1 (Human acute monocytic leukemia cell line), HeLa
(Human cervical cancer cell line), HepG2 (Human liver
hepatocellular carcinoma cell line) and HuH (Human hepatocel-
lular carcinoma cell line) cell lines. THP-1 cells were purchased
from the National cell repository, National Centre for Cell
Science, Pune, India whereas all other cell lines were from
American Type Culture Collection (ATCC), Manassas, USA).
Cells were seeded at a density of 5610
4 cells per well in 1 ml
RPMI (for THP-1) or DMEM (for other cell lines) media
containing 10% FCS and antibiotic-antimycotic mix in a 24 well
plate. The THP-1 cells were activated by the addition of 30 nM
Phorbol 12-myristate 13-acetate for 16 hours at 37uCi n5 %C O 2.
Cells were allowed to adhere overnight and fresh medium
containing various concentrations of compound 9 was added
along with the DMSO control. Cells were incubated for 48 hours
followed by counting for the viable number of cells by using trypan
blue vital dye.
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Figure S1 (a) Analysis of expression and localization of
MtTPS by SDS - PAGE using a 12.5% gel. Lane1- whole cell
lysate of un-induced sample, Lane 2- insoluble fraction of un-
induced sample, Lane 3- soluble fraction of un-induced sample,
Lane 4 - molecular weight markers, Lane 5 – whole cell lysate of
induced sample, Lane 6 – insoluble fraction of induced sample,
Lane 7- soluble fraction of induced sample. (b) Analysis of the
purified MtTPS. Lane 1- lysate, Lane 2- unbound proteins, Lane
3- wash, Lane 4- molecular weight markers, Lane 5-10- eluted
fractions. (The molecular weight markers comprise of proteins
with molecular mass of 97 kDa, 66 kDa, 43 kDa, 29 kDa, 20 kDa
and 14 kDa).
(TIF)
Figure S2 Analysis of the purity of E.coli HMP-kinase
(ThiD) by SDS-Polyacrylamide gel electrophoresis using
12.5% gel. Lane 1- lysate, Lane 2- unbound proteins, Lane 3 –
wash with 20 mM imidazole buffer, Lane 4 – wash with 50 mM
imidazole buffer, Lane 5- molecular weight markers, Lane 6 -20 –
eluted fractions. (The molecular weight markers comprise of
proteins of with molecular mass of 97 kDa, 66 kDa, 43 kDa,
29 kDa, 20 kDa and 14 kDa).
(TIF)
Figure S3 Study of influence of substrate concentrations
[HMP-PP (a) and Thz-P (b)] on the activity of MtTPS.
(TIF)
Figure S4 Sequence alignment of MtTPS with PfTPS
and BsTPS generated by ClustalW. Identical, conserved
substitutions and semi-conserved substitutions of amino acid
residues are represented by asterisk (*), colon (:) and dot (.),
respectively.
(TIF)
Figure S5 Ramachandran plot analysis of MtTPS ho-
mology model (TPS_1XI3). 87.5%, 8.7% and 2.2% of the
residues are located in the most favoured, additionally allowed and
generously allowed regions, respectively with 1.6% of residues in
the disallowed region. The plot was generated by web-based
PROCHECK.
(TIF)
Figure S6 Analysis of the Z-score for MtTPS model by
using PROSA. The observed Z-score (black dot) is well within
the range of scores typically reported for X-ray crystal and NMR
structures of proteins with a similar size.
(TIF)
Figure S7 Analysis of the local quality for MtTPS model
by using PROSA. The plot showing the average energy over
each 40-residue fragment (thick line) confirms the accuracy of the
local model quality with negative energy values all throughout the
sequence.
(TIF)
Table S1 List and ranking of top 39 selected compounds
obtained from Autodock4, DOCK6 and X-Score results.
NA- Not available in top 40 hits.
(DOC)
Supporting Information S1 Chemical structures of the
top 39 selected compounds.
(PDF)
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